The pivotal role of biomarkers in developing targeted cancer therapies – Quest Diagnostics BioPharma Services

Quest Diagnostics BioPharma Services shared a post on LinkedIn:

“The role of diagnostic labs in oncology is undergoing a seismic shift, and it’s one you can’t afford to ignore.

Join Yuri Fesko MD on Monday, September 16 at 1pm to learn about the pivotal role of biomarkers in developing targeted cancer therapies, including how biomarker-driven approaches are streamlining the drug development process.

Essential learning for Pharma innovators.

Read more here.”

Source: Quest Diagnostics BioPharma Services/LinkedIn

Yuri Fesko is the Senior Vice President and Chief Medical Officer at Quest Diagnostics. He also serves as a Board Member for UPMC’s laboratory joint venture with Quest Diagnostics. Previously, he was the Vice Chair of Cancer Strategic Development at the Duke Cancer Institute.